earticle

논문검색

Session V: Industry Level Development and Production of Recombinant Glycoprotein Therapeutics, Chair : Dr. Hyun Ah Kang (Chung-Ang Univ., Korea)

Development of HBV therapeutic vaccine

원문정보

초록

영어

The hepatitis B virus (HBV) is the major cause of liver disease worldwide. The World Health Organization estimates that 2 billion people (one-third of the world's population) have been infected by HBV. Of these, approximately 400 million people have chronic infections that put them at high risk of ultimately developing cirrhosis and cancer of the liver and the death of liver tissue. In China alone, more than 100 million people have chronic HBV infections. The currently available HBV vaccine needs some improvement to induce protection among the nonresponders and also to apply the immune therapy for the chronic carriers. To improve immunogenicity of the HBV vaccine antigen, we have successfully developed a CHO cell line that can express all three types of envelope proteins (L protein, M protein and S protein) in the form of virus-like particles which are observed in the blood of HBV chronic patients. The preS antigens are exposed at the external surface of the particles composed of S antigens and the virus-like particles are properly glycosylated. Using this antigen, we have developed a strong HBV vaccine which can break immune tolerance and induce strong immune responses in a transgenic mouse model.

저자정보

  • Jung Sun Yum Dobeel Corporation

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.